Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) Stock Competitors & Peer Comparison

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, ENTERO.NS has a market cap of 62B. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while ENTERO.NS trades at ₹1,423.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas ENTERO.NS's P/E ratio is 46.91. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to ENTERO.NS's ROE of +0.07%. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to ENTERO.NS. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check ENTERO.NS's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, EVERESTO.BO has a market cap of 2.9B. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while EVERESTO.BO trades at ₹297.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas EVERESTO.BO's P/E ratio is 52.25. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to EVERESTO.BO's ROE of +0.07%. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to EVERESTO.BO. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check EVERESTO.BO's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, QMSMEDI.NS has a market cap of 2.9B. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while QMSMEDI.NS trades at ₹148.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas QMSMEDI.NS's P/E ratio is 21.23. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to QMSMEDI.NS's ROE of N/A. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to QMSMEDI.NS. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check QMSMEDI.NS's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, ACHYUT.BO has a market cap of 1.7B. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while ACHYUT.BO trades at ₹7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas ACHYUT.BO's P/E ratio is 700.00. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to ACHYUT.BO's ROE of +0.01%. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to ACHYUT.BO. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check ACHYUT.BO's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, RAMAVISION.BO has a market cap of 1.7B. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while RAMAVISION.BO trades at ₹161.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas RAMAVISION.BO's P/E ratio is 166.32. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to RAMAVISION.BO's ROE of +0.21%. Regarding short-term risk, NEXUSSURGL.BO is less volatile compared to RAMAVISION.BO. This indicates lower risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check RAMAVISION.BO's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, BALAXI.NS has a market cap of 1.2B. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while BALAXI.NS trades at ₹22.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas BALAXI.NS's P/E ratio is -4.23. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to BALAXI.NS's ROE of +0.01%. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to BALAXI.NS. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check BALAXI.NS's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, BIJHANS.BO has a market cap of 642.2M. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while BIJHANS.BO trades at ₹85.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas BIJHANS.BO's P/E ratio is 570.80. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to BIJHANS.BO's ROE of N/A. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to BIJHANS.BO. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check BIJHANS.BO's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, VIVOBIOT.BO has a market cap of 428.5M. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while VIVOBIOT.BO trades at ₹19.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas VIVOBIOT.BO's P/E ratio is -23.55. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to VIVOBIOT.BO's ROE of -0.03%. Regarding short-term risk, NEXUSSURGL.BO is less volatile compared to VIVOBIOT.BO. This indicates lower risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check VIVOBIOT.BO's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, RAJNISH.BO has a market cap of 396M. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while RAJNISH.BO trades at ₹0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas RAJNISH.BO's P/E ratio is -6.50. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to RAJNISH.BO's ROE of -0.05%. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to RAJNISH.BO. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check RAJNISH.BO's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, CBPL.BO has a market cap of 376.5M. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while CBPL.BO trades at ₹49.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas CBPL.BO's P/E ratio is 12.35. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to CBPL.BO's ROE of +0.10%. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to CBPL.BO. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check CBPL.BO's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, MONOPHARMA.NS has a market cap of 149.3M. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while MONOPHARMA.NS trades at ₹8.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas MONOPHARMA.NS's P/E ratio is 4.83. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to MONOPHARMA.NS's ROE of N/A. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to MONOPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check MONOPHARMA.NS's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, NATURO.BO has a market cap of 51.5M. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while NATURO.BO trades at ₹2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas NATURO.BO's P/E ratio is -5.93. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to NATURO.BO's ROE of -0.02%. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to NATURO.BO. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check NATURO.BO's competition here

Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEXUSSURGL.BO stands at 106.6M. In comparison, EVOQ.BO has a market cap of 42.6M. Regarding current trading prices, NEXUSSURGL.BO is priced at ₹19.49 on the BSE, while EVOQ.BO trades at ₹1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEXUSSURGL.BO currently has a P/E ratio of 228.86, whereas EVOQ.BO's P/E ratio is -17.10. In terms of profitability, NEXUSSURGL.BO's ROE is +0.56%, compared to EVOQ.BO's ROE of -0.01%. Regarding short-term risk, NEXUSSURGL.BO is more volatile compared to EVOQ.BO. This indicates higher risk in terms of short-term price fluctuations for NEXUSSURGL.BO.Check EVOQ.BO's competition here